Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00259376
Registration number
NCT00259376
Ethics application status
Date submitted
25/11/2005
Date registered
29/11/2005
Date last updated
15/02/2010
Titles & IDs
Public title
American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm
Query!
Scientific title
American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)
Query!
Secondary ID [1]
0
0
SR33589B
Query!
Secondary ID [2]
0
0
EFC4788
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ADONIS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atrial Fibrillation
0
0
Query!
Atrial Flutter
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dronedarone (SR33589)
Treatment: Drugs - placebo
Experimental: Dronedarone 400mg bid - dronedarone 400mg tablets
Experimental: Placebo - matching placebo tablets
Treatment: Drugs: Dronedarone (SR33589)
oral administration
Treatment: Drugs: placebo
oral administration
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The primary endpoint of the study is the time from randomisation to first documented AF/AFL recurrence
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
- AF/AFL related symptoms collected at the time of ECG/TTEM recording,
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [2]
0
0
- mean ventricular rate during AF/AFL at first recorded AF/AFL recurrence (12-lead ECG or TTEM)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Secondary outcome [3]
0
0
- time from presumed study drug near steady state defined as D5 midnight to first documented AF/AFL recurrence as indicated by ECG/TTEM recording.
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Query!
Eligibility
Key inclusion criteria
- Patients of either sex aged 21 years or more, in sinus rhythm for at least 1 hour at
the time of randomisation and with at least one ECG-documented AF/AFL episode in the
last 3 months.
Query!
Minimum age
21
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- MAIN CRITERIA (non-exhaustive list, see protocol for details):
Women of childbearing potential without adequate birth control, Pregnant women,
Breastfeeding women, Congestive heart failure NYHA class III or IV, Conditions which
increase the risk of severe antiarrhythmic drug side effects, Severe associated conditions.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2001
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2003
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
629
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
sanofi-aventis Australia administrative office - Macquarie Park
Query!
Recruitment postcode(s) [1]
0
0
- Macquarie Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
New Jersey
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Buenos Aires
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
Laval
Query!
Country [4]
0
0
South Africa
Query!
State/province [4]
0
0
Midrand
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus
rhythm after electrical, pharmacological or spontaneous conversion of atrial
fibrillation/atrial flutter (AF/AFL).
To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of
AF/AFL recurrence.
To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00259376
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ICD CSD
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00259376
Download to PDF